Literature DB >> 35854417

Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?

Elizabeth J Cathcart-Rake1, Kathryn J Ruddy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35854417      PMCID： PMC9552211          DOI： 10.1093/jnci/djac113

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  20 in total

1.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

Authors:  A Buzdar; A Howell; J Cuzick; C Wale; W Distler; G Hoctin-Boes; J Houghton; G Y Locker; J M Nabholtz
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

2.  Menopausal hormone therapy and 20-year breast cancer mortality.

Authors:  Valerie Beral; Richard Peto; Kirstin Pirie; Gillian Reeves
Journal:  Lancet       Date:  2019-08-29       Impact factor: 79.321

3.  Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

Authors:  Mia Fahlén; Tommy Fornander; Hemming Johansson; Ulla Johansson; Lars-Erik Rutqvist; Nils Wilking; Eva von Schoultz
Journal:  Eur J Cancer       Date:  2012-08-11       Impact factor: 9.162

4.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.

Authors:  Lesley Fallowfield; David Cella; Jack Cuzick; Stephen Francis; Gershon Locker; Anthony Howell
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

5.  Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy.

Authors:  Catherine Gordon; Savanah Gonzales; Michael L Krychman
Journal:  Menopause       Date:  2019-04       Impact factor: 2.953

6.  Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).

Authors:  Debra L Barton; Lynne T Shuster; Travis Dockter; Pamela J Atherton; Jacqueline Thielen; Stephen N Birrell; Richa Sood; Patricia Griffin; Shelby A Terstriep; Bassam Mattar; Jacqueline M Lafky; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2017-11-21       Impact factor: 3.603

7.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2015-07-23       Impact factor: 79.321

8.  Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.

Authors:  Lars Holmberg; Ole-Erik Iversen; Carl Magnus Rudenstam; Mats Hammar; Eero Kumpulainen; Janusz Jaskiewicz; Jacek Jassem; Daria Dobaczewska; Hans E Fjosne; Octavio Peralta; Rodrigo Arriagada; Marit Holmqvist; Johanna Maenpaa; Johanna Maenpa
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506

9.  Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women.

Authors:  M Bygdeman; M L Swahn
Journal:  Maturitas       Date:  1996-04       Impact factor: 4.342

10.  Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.

Authors:  Nigel J Bundred; Peter Kenemans; Cheng Har Yip; Matthias W Beckmann; Jean-Michel Foidart; Piero Sismondi; Bo von Schoultz; Rena Vassilopoulou-Sellin; Rachid El Galta; Eugenie Van Lieshout; Mirjam Mol-Arts; Juan Planellas; Ernst Kubista
Journal:  Breast Cancer Res       Date:  2012-01-17       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.